Cargando…
Analysis of serious adverse event: Writing a narrative
One of the reasons that a research molecule undergoes through different phases of clinical trials is to establish the safety and efficacy of the drug. To establish the safety profile of any drug, the most important aspect is to evaluate every adverse event (AE) that a clinical trial individual exper...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950607/ https://www.ncbi.nlm.nih.gov/pubmed/29862205 http://dx.doi.org/10.4103/picr.PICR_52_18 |
_version_ | 1783322913737277440 |
---|---|
author | Nambiar, Indu |
author_facet | Nambiar, Indu |
author_sort | Nambiar, Indu |
collection | PubMed |
description | One of the reasons that a research molecule undergoes through different phases of clinical trials is to establish the safety and efficacy of the drug. To establish the safety profile of any drug, the most important aspect is to evaluate every adverse event (AE) that a clinical trial individual experiences. This detail is provided by any investigator or sponsor through the narratives that is prepared post the analysis of a serious AE. The purpose of this article is to emphasize the importance of these narratives. |
format | Online Article Text |
id | pubmed-5950607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59506072018-06-01 Analysis of serious adverse event: Writing a narrative Nambiar, Indu Perspect Clin Res Pharmacovigilance Perspective One of the reasons that a research molecule undergoes through different phases of clinical trials is to establish the safety and efficacy of the drug. To establish the safety profile of any drug, the most important aspect is to evaluate every adverse event (AE) that a clinical trial individual experiences. This detail is provided by any investigator or sponsor through the narratives that is prepared post the analysis of a serious AE. The purpose of this article is to emphasize the importance of these narratives. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5950607/ /pubmed/29862205 http://dx.doi.org/10.4103/picr.PICR_52_18 Text en Copyright: © 2018 Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Pharmacovigilance Perspective Nambiar, Indu Analysis of serious adverse event: Writing a narrative |
title | Analysis of serious adverse event: Writing a narrative |
title_full | Analysis of serious adverse event: Writing a narrative |
title_fullStr | Analysis of serious adverse event: Writing a narrative |
title_full_unstemmed | Analysis of serious adverse event: Writing a narrative |
title_short | Analysis of serious adverse event: Writing a narrative |
title_sort | analysis of serious adverse event: writing a narrative |
topic | Pharmacovigilance Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950607/ https://www.ncbi.nlm.nih.gov/pubmed/29862205 http://dx.doi.org/10.4103/picr.PICR_52_18 |
work_keys_str_mv | AT nambiarindu analysisofseriousadverseeventwritinganarrative |